All In Biotech

Drug Trial Radar · NCT03436615

A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum

A Phase 2 Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Ascending Dose Study of SB206 in Subjects With Molluscum Contagiosum

Last checked: Nov 19, 2026Latest source record: May 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 256 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

256

Actual

Start

Jan 24, 2018

Primary completion

Nov 3, 2018

Study completion Nov 3, 2018

Sponsor

Lead sponsor
Novan, Inc.Industry
Sponsor type
Industry
Collaborators
Premier Research
First posted
Feb 19, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase 2 multi-center, randomized, double-blind, vehicle-controlled ascending dose study to be conducted in non-immunocompromised subjects with molluscum contagiosum.

Conditions

  • Molluscum Contagiosum

Interventions

  • SB206 4%Drug

    Twice daily

  • SB206 8%Drug

    Twice daily

  • SB206 12%Drug

    Once or twice daily

  • PlaceboDrug

    Once or twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Subjects Achieving Complete Clearance at Week 12Time frame: 12 weeks

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Premier Site# 266

    Scottsdale, Arizona

  • Premier Site# 260

    Santa Ana, California

  • Premier Site# 257

    Thornton, Colorado

  • Premier Site# 264

    Doral, Florida

  • Premier Site# 116

    Newnan, Georgia

  • Premier Site# 251

    Indianapolis, Indiana

  • Premier Site# 253

    Lenexa, Kansas

  • Premier Site# 117

    Louisville, Kentucky

  • Premier Site# 182

    Las Vegas, Nevada

  • Premier Site# 252

    Norman, Oklahoma

  • Premier Site# 237

    Gresham, Oregon

  • Premier Site# 259

    Charleston, South Carolina

  • Premier Site# 255

    Mt. Pleasant, South Carolina

  • Premier Site# 131

    Houston, Texas

  • Premier Site# 167

    Houston, Texas

  • Premier Site# 224

    San Antonio, Texas

  • Premier Site# 256

    Salt Lake City, Utah

  • Premier Site# 267

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.